Cresset Asset Management’s Myriad Genetics MYGN Stock Holding History

Cresset Asset Management’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-12,919	Closed	-$354K	–	2052
2024 Q3	$354K	Buy	12,919 +467	+4%	+$12.6K	﹤0.01%	1722
2024 Q2	$305K	Buy	12,452 +459	+4%	+$10.1K	﹤0.01%	1710
2024 Q1	$256K	Sell	11,993 -1,462	-11%	-$31.4K	﹤0.01%	1657
2023 Q4	$258K	Buy	13,455 +512	+4%	+$8.86K	﹤0.01%	1565
2023 Q3	$208K	Buy	12,943 +2,095	+19%	+$39.9K	﹤0.01%	1606
2023 Q2	$251K	Buy	+10,848	New	+$237K	﹤0.01%	1613
2021 Q4	–	Sell	-7,081	Closed	-$228K	–	1234
2021 Q3	$228K	Buy	+7,081	New	+$235K	﹤0.01%	973
2019 Q2	–	Sell	-121	Closed	-$4K	–	1235
2019 Q1	$4K	Hold	121	–	–	﹤0.01%	1429
2018 Q4	$4K	Buy	+121	New	+$4.35K	﹤0.01%	1107

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Cresset Asset Management's MYGN Position: Q4 2024 in Review

Cresset Asset Management sold out of Myriad Genetics (MYGN) in Q4 2024, closing a stake of 12,919 shares — an estimated $354K sold.

Cresset Asset Management first reported a position in MYGN in Q4 2018 and held it in 9 quarters. The position peaked at $354K in Q3 2024. 221 funds tracked by Wall St. Rank hold MYGN as of Q4 2024.

Cresset Asset Management reported no remaining Myriad Genetics position as of Q4 2024 after selling out during the quarter.
Cresset Asset Management sold 12,919 Myriad Genetics shares in Q4 2024, an estimated $354K.
Cresset Asset Management first reported a position in Myriad Genetics in Q4 2018 and held it in 9 quarters.
Cresset Asset Management's Myriad Genetics position peaked at $354K in Q3 2024.
221 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2024.

Based on Cresset Asset Management's 13F filing for Q4 2024, filed 14 Feb 2025.